UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

Journal of medical economics, 2014-08, Vol.17 (8), p.587-598

2014

Volltextzugriff (PDF)

The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland

International journal of STD & AIDS, 2016-01, Vol.27 (1), p.51-57

2016

Volltextzugriff (PDF)

The Costs of Managing Genital Warts in the UK by Devolved Nation: England, Scotland, Wales and Northern Ireland

Value in health, 2013-11, Vol.16 (7), p.A350-A350

2013

Volltextzugriff (PDF)

Estimating The Lifetime Clinical Risk/Benefits of Apixaban Versus Edoxaban In Non-Valvular Atrial Fibrillation

Value in health, 2015-05, Vol.18 (3), p.A131-A131

2015

Volltextzugriff (PDF)

Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism

Journal of medical economics, 2017-01, Vol.20 (1), p.98-106

2017

Volltextzugriff (PDF)

Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism

Value in health, 2014-11, Vol.17 (7), p.A488-A488

2014

Volltextzugriff (PDF)

Validation Of The Apixaban Cost-Effectiveness Model In Patients With Non-Valvular Atrial Fibrillation

Value in health, 2014-05, Vol.17 (3), p.A113-A113

2014

Volltextzugriff (PDF)

Representing Uncertainty In Economic Evaluations: Getting More From PSA Results

Value in health, 2017-10, Vol.20 (9), p.A749

2017

Volltextzugriff (PDF)

PRM103 - Representing Uncertainty In Economic Evaluations: Getting More From PSA Results

Value in health, 2017-10, Vol.20 (9), p.A749-A749

2017

Volltextzugriff (PDF)

The cost of managing genital warts in the UK

International journal of STD & AIDS, 2012-03, Vol.23 (3), p.189-194

2012

Volltextzugriff (PDF)

PIN35 Costs of Managing Genital Warts in the UK

Value in health, 2011, Vol.14 (7), p.A271-A271

2011

Volltextzugriff (PDF)

Application of New French Guidelines for Economic Evaluations: A Cost-Effectiveness Analysis of Apixaban in Patients with Non-Valvular Atrial Fibrillation in France

Value in health, 2013-11, Vol.16 (7), p.A523-A523

2013

Volltextzugriff (PDF)

Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism

Value in health, 2014-11, Vol.17 (7), p.A475-A475

2014

Volltextzugriff (PDF)

A Wavelet-Domain Local Dominant Feature Selection Scheme for Face Recognition

ISRN machine vision, 2012-03, Vol.2012 (2012), p.1-13

2012

Volltextzugriff (PDF)

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

European heart journal, 2014-07, Vol.35 (28), p.1897-1906

2014

Volltextzugriff (PDF)

VALUE DEMONSTRATION OF IMMUNO-ONCOLOGY THERAPIES IN A RARE TUMOR COMPARING ASCO, NCCN, AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS

Value in health, 2017-05, Vol.20 (5), p.A109

2017

Volltextzugriff (PDF)

COMPARISON OF VALUE EVALUATIONS USING DRUG ABACUS AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS FOR AN IMMUNO-ONCOLOGY DRUG IN AN ORPHAN INDICATION

Value in health, 2017-05, Vol.20 (5), p.A107

2017

Volltextzugriff (PDF)

Value And Cost Conundrum In Advanced Oncology: Integration Of Value Frameworks Into Cost-Effectiveness Analyes

Value in health, 2016-11, Vol.19 (7), p.A399-A399

2016

Volltextzugriff (PDF)

PRM230 - Value And Cost Conundrum In Advanced Oncology: Integration Of Value Frameworks Into Cost-Effectiveness Analyes

Value in health, 2016-11, Vol.19 (7), p.A399-A399

2016

Volltextzugriff (PDF)

PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE: MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGY

Value in health, 2018-10, Vol.21, p.S19-S19

2018

Volltextzugriff (PDF)

Clinical Events Avoided with Apixaban Compared to Edoxaban for the Initial Treatment and Prevention of Venous Thromboembolism

Value in health, 2016-05, Vol.19 (3), p.A48-A48

2016

Volltextzugriff (PDF)

PCV52 - Clinical Events Avoided with Apixaban Compared to Edoxaban for the Initial Treatment and Prevention of Venous Thromboembolism

Value in health, 2016-05, Vol.19 (3), p.A48-A48

2016

Volltextzugriff (PDF)

Projecting Overall Survival (OS) With Immuno-Oncology (IO) Treatments: Application of Alternative Approaches in Metastatic Merkel Cell Carcinoma (MMCC)

Value in health, 2018-05, Vol.21, p.S6

2018

Volltextzugriff (PDF)

CN4 - Projecting Overall Survival (OS) With Immuno-Oncology (IO) Treatments: Application of Alternative Approaches in Metastatic Merkel Cell Carcinoma (MMCC)

Value in health, 2018-05, Vol.21, p.S6-S6

2018

Volltextzugriff (PDF)

PCV46 A SYSTEMATIC LITERATURE REVIEW OF THE INDIRECT COSTS ASSOCIATED WITH STROKE, BLEEDING, AND VITAMIN K ANTAGONIST MONITORING IN ATRIAL FIBRILLATION

Value in health, 2019-05, Vol.22, p.S127-S127

2019

Volltextzugriff (PDF)

1 – 25 von 676

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(387)
Mit Volltextzugriff
(596)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(251)
Computer Science
(158)
Technology
(157)
Life Sciences & Biomedicine
(140)
Computer Science, Artificial Intelligence
(131)
Computer Science, Theory & Methods
(122)
Humans
(105)
Imaging Science & Photographic Technology
(100)
Surgery
(66)
Female
(64)
Male
(52)
Radiology, Nuclear Medicine & Medical Imaging
(46)
Medicine
(45)
Medicine & Public Health
(43)
Middle Aged
(43)
Aged
(41)
Adult
(30)
Deep Learning
(29)
Engineering
(27)
Internal Medicine
(23)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland

The Costs of Managing Genital Warts in the UK by Devolved Nation: England, Scotland, Wales and Northern Ireland

Estimating The Lifetime Clinical Risk/Benefits of Apixaban Versus Edoxaban In Non-Valvular Atrial Fibrillation

Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism

Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism

Validation Of The Apixaban Cost-Effectiveness Model In Patients With Non-Valvular Atrial Fibrillation

Representing Uncertainty In Economic Evaluations: Getting More From PSA Results

PRM103 - Representing Uncertainty In Economic Evaluations: Getting More From PSA Results

The cost of managing genital warts in the UK

PIN35 Costs of Managing Genital Warts in the UK

Application of New French Guidelines for Economic Evaluations: A Cost-Effectiveness Analysis of Apixaban in Patients with Non-Valvular Atrial Fibrillation in France

Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism

A Wavelet-Domain Local Dominant Feature Selection Scheme for Face Recognition

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

VALUE DEMONSTRATION OF IMMUNO-ONCOLOGY THERAPIES IN A RARE TUMOR COMPARING ASCO, NCCN, AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS

COMPARISON OF VALUE EVALUATIONS USING DRUG ABACUS AND TRADITIONAL COST-EFFECTIVENESS ANALYSIS FOR AN IMMUNO-ONCOLOGY DRUG IN AN ORPHAN INDICATION

Value And Cost Conundrum In Advanced Oncology: Integration Of Value Frameworks Into Cost-Effectiveness Analyes

PRM230 - Value And Cost Conundrum In Advanced Oncology: Integration Of Value Frameworks Into Cost-Effectiveness Analyes

PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE: MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGY

Clinical Events Avoided with Apixaban Compared to Edoxaban for the Initial Treatment and Prevention of Venous Thromboembolism

PCV52 - Clinical Events Avoided with Apixaban Compared to Edoxaban for the Initial Treatment and Prevention of Venous Thromboembolism

Projecting Overall Survival (OS) With Immuno-Oncology (IO) Treatments: Application of Alternative Approaches in Metastatic Merkel Cell Carcinoma (MMCC)

CN4 - Projecting Overall Survival (OS) With Immuno-Oncology (IO) Treatments: Application of Alternative Approaches in Metastatic Merkel Cell Carcinoma (MMCC)

PCV46 A SYSTEMATIC LITERATURE REVIEW OF THE INDIRECT COSTS ASSOCIATED WITH STROKE, BLEEDING, AND VITAMIN K ANTAGONIST MONITORING IN ATRIAL FIBRILLATION

Suchergebnisse filtern